International Journal of Hyperthermia 2021 [Link] Parisa Malekzadeh, Meghan Good, Marybeth S Hughes Abstract Introduction: Malignant peritoneal mesothelioma (MPM) is a lethal cancer, with approximately 2% of diagnoses occurring in patients less than 40 years of age. The purpose of this study is to report the only long-term follow up and survival of pediatric patients…

Read More

Chest 2021 June 10 [Link] Rachelle Asciak, Nikolaos I Kanellakis, Anna Bibby, Andrew Kidd, Stephen Gerry, Rachel Mercer, Nick Maskell, Kevin G Blyth, Peter Fsadni, Stephen Montefort, Ioannis Psallidas, Najib M Rahman Abstract Background: Most patients with malignant pleural mesothelioma (MPM) present with malignant pleural effusion (MPE). There is in vitro evidence that MPE may…

Read More

Cytopathology 2021 May 28 [Link] Patrizia Straccia, Daniele Magnini, Rocco Trisolini, Filippo Lococo, Marco Chiappetta, Alessandra Cancellieri Abstract Objective: Malignant mesothelioma (MM) is usually diagnosed by histological examination of tissue samples; however, effusion cytology offers an opportunity to identify a strong possibility for mesothelioma diagnosis at an early stage. We conducted a retrospective analysis of…

Read More

Cytopathology 2021 May 25 [Link] Amber Louw, Y C Gary Lee, Nathan Acott, Jenette Creaney, Chris van Vliet, Siaw Ming Chai Abstract Objective: To assess the utility of BRCA1-associated protein 1 (BAP1) immunohistochemistry (IHC) for the diagnosis of malignant pleural mesothelioma (MPM) in fluid samples with atypical cytology. Methods: Pleural fluid samples with an atypical…

Read More

Chest 2021 June 10 [Link] Rachelle Asciak, Nikolaos I Kanellakis, Anna Bibby, Andrew Kidd, Stephen Gerry, Rachel Mercer, Nick Maskell, Kevin G Blyth, Peter Fsadni, Stephen Montefort, Ioannis Psallidas, Najib M Rahman Abstract Background: Most patients with malignant pleural mesothelioma (MPM) present with malignant pleural effusion (MPE). There is in vitro evidence that MPE may…

Read More

Frontiers in Oncology 2021 April 28 [Link] Rachelle Asciak, Nikolaos I Kanellakis, Xuan Yao, Megat Abd Hamid, Rachel M Mercer, Maged Hassan, Eihab O Bedawi, Melissa Dobson, Peter Fsadni, Stephen Montefort, Tao Dong, Najib M Rahman, Ioannis Psallidas Abstract Objectives: Patients with malignant pleural mesothelioma (MPM) or pleural metastases often present with malignant pleural effusion…

Read More

Anticancer Research 2021 May [Link] Akihiro Shiroshita, Motohiro Kurosaki, Masafumi Takeshita, Yuki Kataoka Abstract Background/aim: Although surgical thoracoscopy is recommended in the diagnosis of malignant pleural mesothelioma (MPM), the invasiveness of this procedure is of strong concern. Our review aimed to evaluate the accuracies of medical thoracoscopy (MT), computed tomography (CT)-guided biopsy, and ultrasound (US)-guided…

Read More

ERJ Open Research 2021 March 22 [Link] Lars Hagmeyer, Stephan Schäfer, Marianne Engels, Anja Pietzke-Calcagnile, Marcel Treml, Simon-Dominik Herkenrath, Matthias Heldwein, Khosro Hekmat, Sandhya Matthes, Andreas Scheel, Jürgen Wolf, Reinhard Büttner, Winfried Randerath Abstract Background: Programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) immune checkpoint inhibitors have been approved for monotherapy…

Read More

Thorax 2021 March 10 [Link] Marie Shamseddin, Joanna Obacz, Mathew J Garnett, Robert Campbell Rintoul, Hayley Elizabeth Francies, Stefan John Marciniak Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer most commonly caused by prior exposure to asbestos. Median survival is 12-18 months, since surgery is ineffective and chemotherapy offers minimal benefit. Preclinical models that…

Read More